NCT03875313View on ClinicalTrials.gov

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 20, 2019

Primary Completion Date

July 29, 2020

Study Completion Date

July 29, 2020

Conditions
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast CancerColorectal CancerCRCRCCccRCC
Interventions
DRUG

CB-839

CB-839 oral tablets administered twice daily with food at the assigned dose level on 28 day cycles with talazoparib.

DRUG

Talazoparib

Talazoparib oral tablets administered at the standard dose once daily with or without food on 28 day cycles with CB-839.

Trial Locations (9)

10032

Columbia University, New York

20000

Huntsman Cancer Institute, Salt Lake City

30322

Winship Cancer Institute of Emory University, Atlanta

35294

University of Alabama, Birmingham

52242

University of Iowa, Iowa City

53792

University of Wisconsin, Madison

77030

MD Anderson, Houston

78229

South Texas Accelerated Research Therapeutics, LLC, San Antonio

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY

NCT03875313 - Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter